AMRX Amneal Pharmaceuticals Inc. Class A

5.32
+0.22  (+4%)
Previous Close 5.1
Open 5.14
Price To Book 7.29
Market Cap 1,591,212,920
Shares 299,100,173
Volume 1,624,694
Short Ratio 0.88
Av. Daily Volume 3,479,406
Stock charts supplied by TradingView

NewsSee all news

  1. Amneal Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday,

  2. Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors

    Three Independent Directors Bring Significant Pharmaceutical, Healthcare and Financial Expertise and Track Records of Creating Value for Shareholders Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company")

  3. Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX) and AvKARE Inc. today announced they have entered into a definitive agreement under which Amneal will acquire a 65.1% majority interest in AvKARE and its related affiliate doing

  4. Amneal Announces the Approval and Launch of Generic Carafate®

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX), today announced that it has received final U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Carafate® (sucralfate)

  5. Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets

    - Company granted 180 days of exclusivity under FDA Competitive Generic Therapy approval pathway for Generic Amicar - Amneal Pharmaceuticals, Inc. (NYSE:AMRX), today announced that it has received final U.S. Food and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 1H 2020.
IPX203
Parkinson's disease
NDA filing planned.
K127
Myasthenia Gravis

Latest News

  1. Amneal Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday,

  2. Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors

    Three Independent Directors Bring Significant Pharmaceutical, Healthcare and Financial Expertise and Track Records of Creating Value for Shareholders Amneal Pharmaceuticals, Inc. (NYSE:AMRX) ("Amneal" or the "Company")

  3. Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX) and AvKARE Inc. today announced they have entered into a definitive agreement under which Amneal will acquire a 65.1% majority interest in AvKARE and its related affiliate doing

  4. Amneal Announces the Approval and Launch of Generic Carafate®

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX), today announced that it has received final U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Carafate® (sucralfate)

  5. Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets

    - Company granted 180 days of exclusivity under FDA Competitive Generic Therapy approval pathway for Generic Amicar - Amneal Pharmaceuticals, Inc. (NYSE:AMRX), today announced that it has received final U.S. Food and

  6. Amneal Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that management will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday, December 3, 2019 at 10:00 a.m.

  7. Amneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis

    ‒ Expands Amneal's Central Nervous System (CNS) Focused Development Pipeline with Orphan Drug ‒ Amneal Pharmaceuticals, Inc. (NYSE:AMRX), today announced that it has entered into a licensing agreement with Kashiv

  8. Amneal Announces Launch of Generic Invega®

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX), today announced that it has launched its generic version of Invega® (paliperidone) extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg. "We are pleased to have received

  9. Amneal to Report Third Quarter 2019 Results on November 6, 2019

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX) will release its third quarter 2019 financial results on Wednesday, November 6, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and

  10. MedicaSafe Announces Partnership with Amneal Pharmaceuticals

    -- MedicaSafe will combine the generic version of Suboxone® (buprenorphine and naloxone) with its smart medication systems to treat opioid dependence-- MedicaSafe, Inc. today announced a partnership with Amneal

  11. Amneal Announces Approval of Generic Version of Amicar®

    - Company granted 180 days of exclusivity under FDA Competitive Generic Therapy approval pathway - Amneal Pharmaceuticals, Inc. (NYSE:AMRX), today announced that it has received approval from the U.S. Food and Drug

  12. Amneal Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on Tuesday, September

  13. NIRI Philadelphia Elects New Board Members

    The Philadelphia Chapter of the National Investor Relations Institute (NIRI) announced its members elected the following new Board of Directors for a twelve month term beginning in June, 2019: President: Donna St